Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SN30000

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

CEN-209

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroids
Multicellular tumour spheroids capture many characteristics of human tumour microenvironments, including hypoxia, and represent… Expand
  • figure 1
  • figure 2
  • table 1
  • table 1
  • figure 3
Is this relevant?
2017
2017
Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice
3-(3-Morpholinopropyl)-7,8-dihydro-6H-indeno[5,6-e][1,2,4]triazine 1,4-dioxide (SN30- 000), an analog of the well-studied… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2015
2015
Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.
Hypoxia is a prevalent feature of many tumors contributing to disease progression and treatment resistance, and therefore… Expand
  • figure 1
  • table 1
  • figure 3
  • figure 4
  • table 2
Is this relevant?
2014
2014
Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5.
SN30000 is a second-generation benzotriazine-N-oxide hypoxia-activated prodrug scheduled for clinical trial. Previously we showed… Expand
Is this relevant?
2014
2014
Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000.
The radical species underlying the activity of the bioreductive anticancer prodrug, SN30000, have been identified by electron… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer.
Triple-negative breast cancer (TNBC) is an aggressive malignancy with poor clinical outcome and few validated drug targets. Two… Expand
Is this relevant?
2013
2013
18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.
UNLABELLED Hypoxia is a significant therapeutic problem for solid tumors because hypoxic cells are treatment-resistant and more… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2012
2012
The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
PURPOSE Benzotriazine-N-oxide bioreductive prodrugs such as tirapazamine and its improved analogue CEN-209 (SN30000) have… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
CEN-209 (SN30000) is a second-generation benzotriazine di-N-oxide currently in advanced preclinical development as a hypoxia… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
PURPOSE Tirapazamine (TPZ) has attractive features for targeting hypoxic cells in tumors but has limited clinical activity, in… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE